Provided by Tiger Trade Technology Pte. Ltd.

DiaMedica Therapeutics Inc.

6.74
+0.22003.37%
Volume:130.95K
Turnover:879.90K
Market Cap:363.17M
PE:-9.42
High:6.87
Open:6.60
Low:6.60
Close:6.52
52wk High:10.42
52wk Low:5.14
Shares:53.88M
Float Shares:28.20M
Volume Ratio:1.23
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7157
EPS(LYR):-0.7000
ROE:-114.62%
ROA:-64.12%
PB:9.47
PE(LYR):-9.63

Loading ...

DiaMedica FY25 net loss widens to $33 million; R&D expenses rise to $25 million

Reuters
·
Mar 31

Press Release: DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights

Dow Jones
·
Mar 31

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 30

DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
Mar 28

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 27

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

DiaMedica Therapeutics to Report Full-Year 2025 Financial Results and Host Conference Call

Reuters
·
Mar 23

DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026

THOMSON REUTERS
·
Mar 23

DiaMedica Therapeutics Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
Mar 13

Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC)

TIPRANKS
·
Mar 09

DiaMedica Therapeutics receives Health Canada clearance to initiate DM199 study

TIPRANKS
·
Mar 05

Health Canada Clears DiaMedica Phase 2 DM199 Preeclampsia Trial

Reuters
·
Mar 05

DiaMedica Therapeutics Inc - to Initiate Phase 2 Dm199 Trial in 2026; US and UK Expansion Planned

THOMSON REUTERS
·
Mar 05

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of Dm199 in Preeclampsia

THOMSON REUTERS
·
Mar 05

DiaMedica Therapeutics to Participate in TD Cowen, Barclays, and Leerink Healthcare Conferences

Reuters
·
Feb 24